Quanterix reports Q3 EPS (73c), consensus (53c)

Reports Q3 revenue $40.2M, consensus $37.8M. “During the third quarter, we delivered on our revenue expectations despite challenging market conditions,” said Masoud Toloue, CEO of Quanterix (QTRX). “Equally important, we achieved key integration milestones from our Akoya transaction – keeping us firmly on track to realize $85 million in annualized synergies and reach cash flow break-even in 2026. Together, we have built a stronger, more scalable company with the foundation to drive sustained growth, profitability, and cash flow in the years ahead. Our Alzheimer’s diagnostics business also continues to accelerate. With a positive Medicare pricing recommendation and expanding partnerships across Asia, we are advancing toward a future where blood-based testing for neurodegenerative disease becomes standard clinical practice – and Quanterix is at the center of that transformation.”